OS Therapies Reports Increased Losses and Financial Developments for Quarter Ending June 30, 2026

OS Therapies Incorporated has reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $19.0 million for the six months ended June 30, 2026, compared to a loss of $8.4 million for the same period in 2025. This increase in losses is attributed primarily to heightened research and development expenses, which surged to approximately $13.4 million from $3.8 million year-over-year. The company's operating expenses for the second quarter of 2026 were approximately $8.6 million, up from $4.8 million in the prior year, reflecting increased costs associated with clinical trials and vendor services.

In terms of liquidity, OS Therapies reported cash and cash equivalents of $205,035 as of June 30, 2026, a decrease from $269,830 at the end of 2025. The company’s total assets increased to $9.9 million, up from $6.8 million at the end of the previous fiscal year, largely due to the recognition of a VAT receivable of $3.1 million. However, total liabilities also rose significantly to $20.7 million from $11.9 million, driven by an increase in accounts payable and accrued expenses, which reached $20.2 million, up from $11.4 million.

Strategically, OS Therapies has made notable advancements, including the completion of a registered direct offering on April 2, 2026, which raised approximately $4.8 million. This funding is earmarked for clinical development activities, including ongoing trials for its lead product candidate, OST-HER2, which targets Osteosarcoma. The company has also engaged in significant regulatory interactions with the FDA and other international agencies, aiming to submit a Biologics License Application (BLA) by September 2026.

Operationally, OS Therapies has expanded its workforce and capabilities, with a focus on advancing its clinical programs. The company has reported an increase in research and development activities, particularly related to its Phase IIb clinical trial for OST-HER2, which has shown promising results in terms of overall survival rates. The company is also preparing for potential geographic expansion and further product development, including the exploration of OST-HER2's applications in other solid tumors.

Looking ahead, OS Therapies faces challenges related to its liquidity and ongoing operational losses. The company has indicated that it will need to secure additional capital to fund its research and development efforts and maintain operations. Management is actively pursuing equity and debt financing options to address these needs, while also managing operational expenditures to navigate the current financial landscape. The outlook remains contingent on the successful advancement of its clinical programs and the ability to secure necessary funding.